SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

SNDX is trending due to recent FDA approval of Revuforj, sparking community excitement about the drug's potential in treating specific types of leukemia. The approval has triggered discussions around a possible short squeeze, given the stock's high short interest. Some in the community are comparing SNDX to other companies in the AML space, while others are speculating about acquisition potential.

Newegg Commerce, Inc. is an e-commerce company. It offers direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products. The firm also provides third-party logistics services globally. The company was founded on July 22, 2003 and is headquartered in City of Industry, CA.

Newegg Commerce Inc

NEGG is trending as traders discuss its potential for a short squeeze, fueled by high borrowing costs for shorts and a relatively small float. Community members are analyzing short interest data and speculating on potential catalysts, including further insider buying. Some traders express concerns about potential manipulation and are closely watching order flow and short selling activity.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Next, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Next segment is involved in the expenses and investments for emerging business initiatives aimed at creating value for Ford in vehicle-adjacent market segments. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is trending amid discussions around its Q3 earnings, with community members weighing in on whether to buy puts or take profits, particularly with Ford cutting its 2025 adjusted EBIT view. Despite positive earnings, the fire at the Novelis plant and its potential impact on future production are key concerns. Broader market sentiment and the stock's technical levels are also being closely watched.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QS is trending as investors digest news of progress in solid-state battery development, including the shipment of B1 samples and first customer billings, sparking discussions about future partnerships and commercialization. The community is focused on identifying potential OEM partners and debating the company's long-term potential, highlighting both bullish and bearish perspectives. Discussions also include the company's cash runway and path to profitability within the broader context of the EV battery landscape.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending as traders discuss a potential earnings beat and the possibility of a short squeeze, while closely monitoring volume and key price levels. Community members are speculating on news catalysts related to FDA decisions and pipeline developments, drawing comparisons to other companies with similar catalysts. Some investors believe the stock is undervalued, citing strong revenue potential and positive data from recent presentations.

Unusual Machines, Inc. is a development stage technology company, which engages in the provision of drone solutions with a focus on first-person view (FPV) technology. It offers products to entertainment, recreation, and competitive racing industries. The company was founded on July 11, 2019, and is headquartered in Orlando, FL.

Unusual Machines Inc

Unusual Machines, Inc.

Unusual Machines is trending due to a recently announced $800,000 contract with Red Cat Holdings for drone components, signaling growth and increased demand for US-made drone parts. The community is discussing the implications of this deal, particularly in light of upcoming government funding decisions and the potential for further contract wins. Some investors are also highlighting Unusual Machines' strategic investments in other drone-related companies.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending due to reports about its progress in quantum computing error correction utilizing AMD chips, sparking renewed interest in the quantum sector; the community is discussing IBM's potential leadership in quantum computing and its attractive valuation compared to zero-revenue companies. Bullish sentiment is building as some investors view this development as a major leap toward commercializing quantum computers, while others remain skeptical about the near-term impact on revenue.

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Neuphoria Therapeutics Inc.

NEUP is trending due to a significant surge potentially fueled by news of insider buying and a milestone payment from Merck related to their Alzheimer's program. The community is actively discussing the low float and potential for a short squeeze, with some speculating about a potential run to double digits. However, some traders caution about potential dilution.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

LUMN is trending as investors discuss its potential in the AI infrastructure space, particularly following news of a partnership. Community members are focused on the stock's long-term prospects and potential for a short squeeze, while acknowledging the company's debt. The discussion highlights the potential for LUMN to transition from legacy telecom to a key player in the AI-driven economy.

Why Queen Kitty ($QKitty) Is The Meme Token You’ve Been Waiting For  Queen Kitty isn’t just another hype project—this is a real movement with substance and community power!  Why hold $QKitty? 😼 Real dev, real builds: No fake teams, no copy-paste code. Everything you see is made from scratch. 💧 Working Faucet: Free QKitty for the community. Want to know how? Just ask! 🏆 Big Buy Competition Bot: See top buyers live, fight for the throne, and win rewards! 🎮 Multi-token P2E game coming soon: Play and earn across Web, iOS, Android! 🐾 NFT collecting soon: Cutest collection in crypto, bringing perks and more ways to earn.  Queen Kitty means innovation, transparency, and real delivery for holders. Curious? Join the chat and ask anything!  $QKitty: By the community, for the community. To the moon, together! 🚀🐱

Queen Kitty

Queen Kitty ($QKITTY) is gaining attention, with community members expressing excitement about potential gains.  Discussion centers around new updates, holding strong, and the project's trading bot feature offering daily interest. The community also seems excited about collaboration and airdrops with $BROKE.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LENZ Therapeutics, Inc. (LENZ) Upgraded to Buy: What Does It Mean for the Stock?

LENZ Therapeutics, Inc. (LENZ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

LENZ Therapeutics, Inc. (LENZ) is a Great Momentum Stock: Should You Buy?

Does LENZ Therapeutics, Inc. (LENZ) have what it takes to be a top stock pick for momentum investors? Let's find out.

Does LENZ Therapeutics, Inc. (LENZ) Have the Potential to Rally 30.86% as Wall Street Analysts Expect?

The consensus price target hints at a 30.9% upside potential for LENZ Therapeutics, Inc. (LENZ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Blindness-Focused LENZ Therapeutics' Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst Says

Advances in presbyopia treatment with LENZ Therapeutics' LNZ100. Clinically proven to enhance near-vision for up to 10 hours, it offers a promising alternative to reading glasses. Analysts predict a...

LENZ Therapeutics gains as eye therapy succeeds in late-stage trial

LENZ Therapeutics gains as eye therapy succeeds in late-stage trial...

Lenz Therapeutics announces results from Phase 3 CLARITY study

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials

LENZ Therapeutics, Inc. (Nasdaq: LENZ or LENZ or the Company), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop to improve near vision in...

LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials

LENZ Therapeutics, Inc. (Nasdaq: LENZ or LENZ or the Company), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve...

Huge Insider Buying From Buffett, an NFL Team Owner, a New CEO

Yet again, the Oracle of Omaha has bolstered his stake in a media giant's tracking stocks. However, Warren Buffett was not the only one making notable insider purchases in the past week or so. An NFL...

LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress

LENZ Therapeutics, Inc. (Nasdaq: LENZ) (LENZ or the Company), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve...

LENZ Therapeutics, Inc. is a pre-commercial biopharmaceutical company, which focuses on the development and commercialization of innovative therapies to improve vision. It offers eye drop product treatment for presbyopia. The company was founded by James W. McCollum in July 2013 and is headquartered in Solana Beach, CA.

LENZ Therapeutics Inc.

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

LENZ
LENZ Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest LENZ News

LENZLENZ Therapeutics Inc.